Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders (vol 55, pg 330, 2018)

被引：0
|
作者：
Kocaman, Gulsen [1 ]
Kahraman, Nese [2 ]
Gurkan Koseoglu, Banu [2 ]
Bilgic, Basar [3 ]
Matur, Zeliha [4 ]
Ertas, Mustafa [5 ]
Gulsen, Yesim [3 ]
Baykan, Betul [3 ]
机构：
[1] Bezmialem Vakif Univ, Dept Neurol, Fac Med, Istanbul, Turkey
[2] Istanbul Univ, Istanbul Fac Dent, Dept Maxillofacial Surg, Istanbul, Turkey
[3] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Istanbul, Turkey
[4] Istanbul Bilim Univ, Dept Neurol, Fac Med, Istanbul, Turkey
[5] Private Off, Neurol, Istanbul, Turkey
来源：
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY | 2019年 / 56卷 / 01期
关键词：
D O I：
10.29399/npa.23634
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：83 / 83
页数：1
相关论文
共 50 条
  • [31] Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
    Silberstein, Stephen D.
    Dodick, David W.
    Aurora, Sheena K.
    Diener, Hans-Christoph
    DeGryse, Ronald E.
    Lipton, Richard B.
    Turkel, Catherine C.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (09): : 996 - 1001
  • [32] The Percent of Chronic Migraine Patients Who Responded to OnabotulinumtoxinA Treatment Per Treatment Cycle in the PREEMPT Clinical Program
    Silberstein, Stephen
    Dodick, David
    DeGryse, Ronald
    Lipton, Richard
    Turkel, Catherine
    NEUROLOGY, 2012, 78
  • [33] The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
    Silberstein, S.
    Dodick, D. W.
    DeGryse, R. E.
    Lipton, R.
    Turkel, C. C.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [34] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Brin, Mitchell F.
    CEPHALALGIA, 2017, 37 : 93 - +
  • [35] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Brin, Mitchell F.
    Winner, Paul
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    NEUROLOGY, 2018, 90
  • [36] The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
    S Silberstein
    DW Dodick
    RE DeGryse
    R Lipton
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
  • [37] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, P. K.
    Blumenfeld, A.
    Eross, E. J.
    Orejudos, A.
    Adams, Manack A.
    Brin, M. F.
    HEADACHE, 2018, 58 : 105 - 105
  • [38] Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis
    Young, William B.
    Lopez, J. Ivan
    Rothrock, John F.
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    CEPHALALGIA, 2017, 37 : 100 - 101
  • [39] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Paul K. Winner
    Andrew M. Blumenfeld
    Eric J. Eross
    Amelia C. Orejudos
    Debbie L. Mirjah
    Aubrey Manack Adams
    Mitchell F. Brin
    Drug Safety, 2019, 42 : 1013 - 1024
  • [40] Treatment of Chronic Migraine Using OnabotulinumtoxinA May be Less Effective in Pediatric Patients with History of Depression or Anxiety
    O'Brien, H.
    Kabbouche, M.
    Kacperski, J.
    Hershey, A. D.
    Horn, P.
    Vaughan, P.
    Slater, S.
    Wood, B.
    HEADACHE, 2014, 54 : 45 - 45
12345